Mineralys Therapeutics Gains FDA NDA Acceptance for Lorundrostat with December 2026 PDUFA Date

With a PDUFA target date of December 22, 2026 now on the calendar, Mineralys Therapeutics has entered the pre-approval window that demands full CMC readiness, process validation completion, and manufacturing site preparedness well ahead of any potential FDA inspection. The NDA acceptance for lorundrostat, an aldosterone synthase inhibitor indicated for hypertension in combination with other antihypertensive agents, shifts the operational burden squarely onto manufacturing and quality functions.

The NDA package drew on five pivotal clinical trials demonstrating blood pressure reduction and 24-hour control in adults with uncontrolled or resistant hypertension. An ongoing Transform-HTN open-label extension continues to generate long-term safety and efficacy data that may be relevant to post-approval commitments and labeling negotiations. For regulatory affairs leads, the extension trial represents a live data stream that must be managed in parallel with the review cycle.

On the financial side, R&D spend for Q1 2026 fell to $24.4 million from $37.9 million in Q1 2025, reflecting a $15.5 million reduction in clinical costs following conclusion of the lorundrostat pivotal program in Q2 2025. That contraction was partially offset by a $1.1 million increase in clinical supply, manufacturing, and regulatory costs, a line item that signals active CMC scale-up activity consistent with pre-approval manufacturing expectations under 21 CFR Part 211. G&A expenses rose sharply to $21.0 million from $6.6 million year-over-year, driven by headcount growth and professional fees associated with pre-commercial build-out.

Mineralys reported cash, equivalents, and investments of $646.1 million as of March 31, 2026, down modestly from $656.6 million at year-end 2025. The company projects this runway extends into 2028, covering planned clinical and regulatory activities alongside commercial preparation. For plant heads and QA directors at contract manufacturing partners, the funding position reduces near-term supply continuity risk during the approval transition.

Pre-commercial activities underway include market access discussions and sales and marketing preparation, but the more immediate operational checkpoint is manufacturing readiness: process validation data packages, batch records, and any pre-approval inspection responses must be defensible before the PDUFA date arrives.

The December 22, 2026 PDUFA date gives manufacturing and quality teams roughly seven months to close any outstanding process validation gaps and ensure facility readiness aligns with FDA pre-approval inspection timelines.

Source: Mineralys Therapeutics, Inc. via GlobeNewswire, May 6, 2026. Conference call held same day at 4:30 p.m. ET.